Market news

Cellectis S.A. (NASDAQ:CLLS) announced on September 14 that its board approved a strategic transformation on September 11. It will exit internal development of lasme-cel and eti-cel, seek partners for those cancer therapies, and prioritize two preclinical programs for severe lipid disorders. The shift moves the internal pipeline toward in vivo treatment, delivering editing machinery directly […]

Cellectis pivots to in vivo gene editing, exiting ex-vivo CAR-T programs due to shrinking commercial opportunities. Read why CLLS stock is a hold.

Cellectis is shifting its development strategy toward in vivo gene editing after reporting preclinical proof-of-concept for. HEAL-101 and.

Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.

Cellectis (CLLS) shares were down nearly 40% in Monday trading after the company said it will realig

Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectivelyTransformation supported by continuing existing cell therapy partnerships while exiting lasme-cel and eti-cel developmentRealignment of the operating model targeting Cellectis cash runway extension into H2 2028Conference call and webcast on September 14: English at 8 a.m. ET, French at 9 a.m. ET NEW YORK, Sept. 14, 2026 (GLOBE NE

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update. Conference Call and Webcast Details: September 14, 2026 English-language at 8:00 a.m. ET. / 2:00 p.m. CET Webcast link:https://viavid.

Tipranks Press Release.

(Article 223-16 of General Regulation of the French financial markets authority)PARIS, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights08/31/2026100,718,974105,568,956 For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 7

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will participate in the upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference – Boston, MASeptember 10, 2026 Baird 2026 Global Healthcare Conference – New YorkSeptember 15, 2026Company presentation at 12:50 - 1:

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company...

Detailed price information for Cellectis Romainville Ord (CMVLF) from The Globe and Mail including charting and trades.

(Article 223-16 of General Regulation of the French financial markets authority)PARIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights07/31/2026100,701,207105,554,794 For further information on Cellectis, please contact: Media contacts:Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.comPatricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 4

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2026 ending June 30, 2026 on Thursday, August 6, 2026 after the close of the US market. The press release will be available in the Investors section of Cellectis’ website: https://www

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Multiple Myeloma pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Myeloma treatment therapies, analysis of Clinical Trials, Ther...